Great Debates and Updates in Gastrointestinal (GI) Malignancies

Great Debates and Updates in Gastrointestinal (GI) Malignancies is organized by Healthcare Made Practical (HMP) Communications LLC. This course will be held from Aug 14 - 15, 2020.

Accreditation:
Physicians
NACCME designates this enduring activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants are not eligible to receive credit for any part of this enduring material if credit was claimed as part of the live event.

Pharmacy
This enduring, knowledge-based activity (JA0006201-9999-20-115-H01-P) has been approved for a maximum of 16 contact hours (1.6 CEUs). Participants are not eligible to receive credit for any part of this enduring material if credit was claimed as part of the live event.

Nursing
This enduring continuing nursing education activity awards 16 contact hours. This activity will also award pharmacotherapeutic contact hours; however, the final assignment of these contact hours will be announced once all content has been approved. Participants are not eligible to receive credit for any part of this enduring material if credit was claimed as part of the live event.

Physician Assistants
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet live activity is designated for 16 AAPA Category 1 credits. Participants are not eligible to receive credit for any part of this enduring material if credit was claimed as part of the live event.

Description:
Featuring a comprehensive review of the latest clinical advancements in gastrointestinal malignancies, robust audience engagement, and ample discussion, participants will leave equipped with practical implications and applications to put into practice immediately.

Learning Objectives:
• Analyze the mechanism of action (MOA) and safety-efficacy profiles of currently approved and emerging oncological agents including immunotherapies for the management of GI malignancies
• Integrate clinical trial data and evidence-based therapies for improving clinical outcomes in patients with GI malignancies
• Evaluate the best practices and standards of care based on a multidisciplinary approach for the management of GI cancers
• Implement the rational use of immunotherapies in patients with GI malignancies on a case-by-case basis
• Define patient populations most suitable for enrolling in GI clinical trials for progressive advanced stage GI malignancies
• Implement optimal management strategies for both metastatic and non-metastatic GI malignancies based on personalized factors such as comorbidities, cost, disease stage, and prior therapeutic regimens